BMBenjamin Martin

Benjamin Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin Martin has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Congenital heart disease in pregnancy and severe maternal morbidity: A distributed data network study

    by Elizabeth B. Sherwin, Benjamin Martin, Xiao Xu, Anna Booman, Alyssa Howren, Kimberlee McKay, Sadaf Kazi, Sean O'REilly, Katie S. Kolla, Khyzer Aziz, et al.

    Introduction: Pregnant people with congenital heart disease (CHD) are a growing patient population in obstetrics, yet evidence on the risk for severe maternal morbidity (SMM) has largely been limited to studies that lack specificity for CHD. We conducted this study to demonstrate the utility of distributed data networks for obstetric research and to characterize pregnant patients with CHD and their risk of SMM. Methods: The study included female patients aged 12–55 years who delivered between 2015 and 2026 at three US academic healthcare organizations. We used a distributed data network study design by developing analytical code, executing the code locally at each organization using its electronic health record (EHR) data in a common data model (CDM), then aggregating the results. This analytical approach is rigorous, is reproducible, and protects patient confidentiality by not sharing patient‐level data. The Observational Medical Outcomes Partnership (OMOP) CDM was used by each organization, and we used OMOP standard concepts to identify CHD and SMM. We categorized outcomes as SMM, non‐transfusion SMM, and cardiac SMM based on the CDC SMM index. We analyzed the incidence of the outcomes and estimated risk ratios (RRs) and Wald 95% confidence intervals (CIs) using contingency tables. Results: The prevalence of CHD in pregnancy was 2.20% among 166,033 deliveries across three healthcare organizations. A total of 19.30% of people with CHD had an acquired heart condition, compared to 2.14% of people without CHD. SMM occurred in 9.43% of deliveries to people with CHD compared to 4.53% among people without CHD (RR, 2.08; 95% CI, 1.88, 2.31), and non‐transfusion SMM occurred in 6.72% vs 2.55% of deliveries (RR, 2.63; 95% CI, 2.33, 2.98), respectively. Cardiac SMM represented 51.84% of non‐transfusion SMM among people with CHD compared to 16.18% among people without CHD. Conclusions: Our distributed data network study using EHR data from three geographically diverse US healthcare organizations found that one in 15 people with CHD had non‐transfusion SMM compared with one in 39 people without CHD. This study demonstrates the feasibility and utility of distributed data networks for obstetric research and provides novel evidence on maternal outcomes for pregnant patients with CHD.

  • Open Access

    A Computable Phenotype for Planned Tracheostomy Events to Characterize Outcomes and Measure Time Toxicity in Critical Care Settings (Preprint)

    by Benjamin Martin

    BACKGROUND Tracheostomy is a frequently performed procedure in critical care settings, but procedures are often inconsistently coded in electronic health records (EHRs), with explicit designation as elective or emergency frequently absent. This coding ambiguity limits the ability to identify planned tracheostomy cohorts for observational research on outcomes and time toxicity. Common data models such as the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) enable large-scale federated research, but require validated computable phenotypes to ensure reliable cohort identification across heterogeneous data sources. OBJECTIVE To develop and validate a computable phenotype that identifies elective tracheostomy procedures from EHR data standardized to the OMOP CDM, enabling scalable and reproducible analysis of tracheostomy-related time toxicity in critically ill patients. METHODS We conducted a retrospective observational study using EHR data from the Johns Hopkins Health System from 2017 to 2024, comprising approximately 2.1 million patients with data mapped to the OMOP CDM. A series of cohort definitions were developed using standardized clinical code sets (International Classification of Diseases, 10th Revision [ICD-10] and Current Procedural Terminology [CPT]) from the Observational Health Data Sciences and Informatics (OHDSI) Standardized Vocabularies. To classify tracheostomy procedures lacking explicit urgency coding, we compared covariate prevalence and temporal relationships (e.g., intubation timing relative to tracheostomy) between explicitly coded elective and emergency cohorts. Six candidate computable phenotypes with stepwise inclusion and exclusion criteria were evaluated using PheValuator, a validated probabilistic phenotype evaluation tool. RESULTS Among 3552 patients with a tracheostomy procedure identified between 2017 and 2024, 2484 (69.9%) were explicitly coded as elective and 107 (3.0%) as emergency; the remaining 961 (27.1%) lacked explicit urgency classification. Covariate analysis revealed significant differences in intubation timing, drug exposures, and procedure codes between the explicitly coded groups. The best-performing computable phenotype (Cohort #202), which used inpatient visit-based attribution of planned and emergency codes, achieved a sensitivity of 0.88 (95% CI 0.84-0.91) and a positive predictive value (PPV) of 0.81 (95% CI 0.77-0.84), with an F1 score of 0.84. CONCLUSIONS The proposed computable phenotype effectively distinguishes elective from emergency tracheostomy in structured EHR data. This approach enables large-scale, reproducible studies of tracheostomy-related time toxicity across heterogeneous OMOP-mapped data sources and provides a generalizable framework for phenotyping intent-ambiguous procedures across federated research networks.

  • Open Access

    Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

    by Cindy X. Cai, Brian Toy, Benjamin Martin, Ruochong Fan, Erik Westlund, Diep Tran, Akihiko Nishimura, Haeun Lee, Theodore Leng, Paul Nagy, et al.


  • Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency

    by Seonji Kim, Jimyung Park, Hsin Yi Chen, Christianus Heru Setiawan, Haeun Lee, Benjamin Martin, Kyung Joo Lee, George Hripcsak, Jason C. Hsu, Paul Nagy, et al.

    BACKGROUND: Proton pump inhibitors (PPIs) may potentially reduce clopidogrel’s antiplatelet effect and increase cardiovascular risk. The degree of CYP (cytochrome P450) 2C19 inhibition varies among PPIs. Few studies have evaluated individual PPIs by CYP2C19 inhibition strength across countries. This study aimed to compare the incidence of cardiovascular events between strong CYP2C19-inhibiting potency and weak CYP2C19-inhibiting potency (weak or non-CYP2C19–inhibiting PPIs) in patients receiving clopidogrel. METHODS: We conducted an international observational cohort study using 14 databases from the United States, South Korea, and Taiwan. We included patients aged ≥18 years who received clopidogrel with PPIs from 1985 to 2023. PPIs were classified into strong CYP2C19-inhibiting PPIs and weak or non-CYP2C19–inhibiting PPIs based on CYP2C19 inhibition. We compared the hazard ratios and 95% CIs for major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, using the Cox proportional hazards model after 1:1 propensity score matching. Secondary outcomes included cardiovascular mortality, myocardial infarction, stroke, and all-cause mortality. A random-effects model calculated pooled hazard ratios and 95% CIs. Only databases meeting all diagnostic criteria were included in the meta-analysis. RESULTS: Large-scale propensity score matching identified 166 005 patient pairs. During the 365-day follow-up, the risk of major adverse cardiovascular events did not differ significantly between patients receiving clopidogrel plus strong CYP2C19-inhibiting PPIs and those receiving clopidogrel plus weak or non-CYP2C19–inhibiting PPIs (17.63 per 1000 person-years versus 16.82 per 1000 person-years; calibrated hazard ratio, 1.00 [95% CI, 0.79–1.26]). No significant difference was observed in the risk of secondary outcomes (calibrated hazard ratio, cardiovascular mortality 1.10 [95% CI, 0.87–1.39], myocardial infarction 0.98 [95% CI, 0.81–1.19], stroke 1.05 [95% CI, 0.87–1.27], and all-cause mortality 1.18 [95% CI, 0.93–1.50]). CONCLUSIONS: Concomitant use of clopidogrel and strong CYP2C19-inhibiting PPIs was not associated with a higher cardiovascular risk compared with concomitant use of clopidogrel and weak or non-CYP2C19–inhibiting PPIs. This large-scale study does not support the clinical significance of potential interactions between PPIs and clopidogrel.


  • Identification of Adult Patients With Dermatomyositis Using Real‐World Data Sources

    by Benjamin Martin, Will Kelly, Hannah Morgan‐Cooper, Thomas Falconer, Elizabeth Park, Priya Desai, David Fiorentino, Lorinda Chung, Sean Yen, Zachary Wang, et al.

    Objective: Studying rare diseases like dermatomyositis (DM) in single‐center cohorts is challenging due to small sample sizes and limited generalizability. This study develops and evaluates case identification algorithms for DM to enable coordinated analysis across multiple data sources. Methods: Case identification algorithms were developed to identify adult patients with DM within 11 independent electronic health record or claims databases, totaling over 800 million patients, using the Observational Medical Outcomes Partnership Common Data Model. Algorithm performance was assessed through manual chart review and using Observational Health Data Sciences and Informatics open‐source tools (CohortDiagnostics and PheValuator), which quantify incidence rates and performance metrics such as sensitivity and positive predictive value (PPV). Results: Eight DM case identification algorithms were evaluated across 11 databases, revealing significant variability in performance, with sensitivity and PPV differing by more than 30% between some databases. Overall, we identified one incidence algorithm and one prevalence algorithm with good performance, demonstrated by sensitivity rates of 42% and 49% and PPV values of 83% and 84%, respectively. PheValuator quantified algorithm performance within each database, allowing for direct comparison of different criteria. Additionally, CohortDiagnostics generated incidence rates stratified by age decile and sex, aligning with previous epidemiologic data. Conclusion: We developed and validated multiple DM case identification algorithms across diverse databases, demonstrating their accuracy through multiple evaluation methods. This approach enables more generalizable, reproducible research using real‐world data and can be applied to other rheumatic diseases.


  • Open Access

    Treatment in the First Month After Hypertension Diagnosis Improves Blood Pressure Control

    by Robert B. Barrett, Benjamin Riesser, Benjamin Martin, Neha Sachdev, Michael K. Rakotz, Susan E. Sutherland, Brent M. Egan

    BACKGROUND: Adults with hypertension have fewer cardiovascular events if controlled within the first 6 months of diagnosis, during which time they are excluded from many hypertension control metrics. We compared blood pressure (BP, mm Hg) control rates from 6 to 42 months in adults with hypertension who did or did not have antihypertensive treatment initiated (TI) with monotherapy during the first month after diagnosis, irrespective of subsequent changes in antihypertensive pharmacotherapy. METHODS: A retrospective cohort of 15 422 patients, mean age 56.0±14.8 years, from 5 health care organizations, was identified with previously undiagnosed and untreated hypertension. BP control (P P 30% of patients.


  • Surgical factors affecting return of renal function after partial nephrectomy

    by Janet Colli, Benjamin Martin, Matthew Purcell, Young-Il Kim, Erik J. Busby

    Nephron-sparing surgery is becoming the standard treatment for small renal tumors. In this study, we investigate the relationship between operative factors and recovery of renal function after partial nephrectomy. Records of 141 partial nephrectomy patients at the University of Alabama Medical Center at Birmingham between 1999 and 2008 were reviewed retrospectively. Renal function was assessed preoperatively, at 1 day (early) and 6 months (late) postoperatively by calculated creatinine clearance (CC). Anesthesia time, arterial clamp time, use of ice slush, tumor size, and change in hematocrit following surgery were assessed for their impact on change in early and late renal function after adjusting for patient age, gender, race, co-morbidities, preoperative renal function and operative approach. Descriptive statistics are presented for independent predictors and research outcome by time points. Multivariate regression model was used to identify independent predictors of renal function. Increasing anesthesia time, clamp time, and postoperative hematocrit were associated with decreased renal function (CC) at 1 day postoperative. At 6 months, tumor size and change in early postoperative hematocrit predicted a decline in CC. In multivariate analysis, decreased renal function at 6 months was predicted by change in postoperative hematocrit level. Long hilar clamp times and anesthesia times adversely affect early postoperative renal function but not late renal function. Intraoperative bleeding adversely affected renal function at both early and late time points. Limiting intraoperative blood loss may be more important than clamp times or renal cooling in the recovery of renal function after partial nephrectomy.


  • 800Surgical aspects and graft outcome in the multi-retransplant kidney patient

    by J. Gutiérrez-Banos, E. Rodrigo, H. Rebollo, J. Portillo, M. Correas, A. Roca, J. Del Valle, B. Martin, M. Arias